Avalo Book Value Per Share from 2010 to 2024

AVTX Stock

USD 9.23 0.12 1.32%

Avalo Therapeutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to 24.98 in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Avalo Therapeutics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

26.2992075

Current Value

24.98

Quarterly Volatility

6.8 K

Credit Downgrade

Yuan Drop

Covid

Check Avalo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avalo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 150.1 K, Interest Expense of 5.6 M or Selling General Administrative of 11.9 M, as well as many indicators such as Price To Sales Ratio of 1.25, Dividend Yield of 0.0 or PTB Ratio of 0.33. Avalo financial statements analysis is a perfect complement when working with Avalo Therapeutics Valuation or Volatility modules.

Check out the analysis of Avalo Therapeutics Correlation against competitors.

For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.

Latest Avalo Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Avalo Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Avalo Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Avalo Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 2.18 X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Avalo Book Value Per Share Regression Statistics

	Arithmetic Mean	3,990
	Coefficient Of Variation	170.15
	Mean Deviation	5,224
	Median	637.78
	Standard Deviation	6,790
	Sample Variance	46.1M
	Range	17.2K
	R-Value	(0.35)
	Mean Square Error	43.7M
	R-Squared	0.12
	Significance	0.21
	Slope	(525.35)
	Total Sum of Squares	645.4M

Avalo Book Value Per Share History

	2024	24.98
	2023	26.3
	2022	-278.43
	2021	637.78
	2020	962.8
	2019	1057.74
	2018	1731.63

Other Fundumenentals of Avalo Therapeutics

Tangible Book Value Per Share

Avalo Therapeutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Short Term Debt	Net Receivables	Net Tangible Assets	Good Will	Net Invested Capital	Net Working Capital	Intangible Assets	Property Plant Equipment	Long Term Debt	Short Long Term Debt	Capital Stock	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.78	-0.27	-0.48	0.45	0.57	0.81	0.21	0.63	-0.3	0.83	0.31	0.21	0.38	0.58	-0.25	0.55	0.54	0.45	0.42	-0.06	-0.06
Total Stockholder Equity	0.78		-0.38	-0.35	0.15	-0.04	0.57	0.4	0.46	-0.46	0.66	0.33	0.02	0.18	0.42	-0.26	0.4	0.55	0.42	0.3	-0.11	-0.11
Net Debt	-0.27	-0.38		0.18	-0.18	0.07	-0.62	0.09	-0.77	0.42	0.13	-0.42	0.2	-0.39	-0.75	0.39	-0.26	-0.58	-0.3	-0.61	0.07	0.07
Retained Earnings	-0.48	-0.35	0.18		-0.15	-0.19	-0.37	0.15	-0.24	0.01	-0.1	0.52	0.6	0.41	-0.37	0.81	-0.93	-0.22	-0.84	0.27	0.63	0.63
Accounts Payable	0.45	0.15	-0.18	-0.15		0.61	0.63	-0.06	0.65	0.17	0.41	0.42	0.48	0.44	0.54	-0.33	0.39	0.64	0.43	0.63	0.51	0.51
Total Liab	0.57	-0.04	0.07	-0.19	0.61		0.6	-0.15	0.45	0.17	0.53	0.19	0.45	0.49	0.39	0.03	0.32	0.18	0.16	0.39	0.29	0.29
Total Current Assets	0.81	0.57	-0.62	-0.37	0.63	0.6		-0.03	0.87	-0.18	0.55	0.47	0.24	0.62	0.86	-0.35	0.54	0.69	0.47	0.72	0.18	0.18
Common Stock	0.21	0.4	0.09	0.15	-0.06	-0.15	-0.03		0.01	-0.14	0.22	0.06	0.07	0.08	-0.05	0.15	-0.2	-0.09	-0.19	0.05	0.11	0.11
Current Deferred Revenue	0.63	0.46	-0.77	-0.24	0.65	0.45	0.87	0.01		-0.32	0.33	0.59	0.2	0.66	0.88	-0.32	0.4	0.72	0.38	0.84	0.21	0.21
Short Term Debt	-0.3	-0.46	0.42	0.01	0.17	0.17	-0.18	-0.14	-0.32		-0.28	-0.46	0.22	-0.25	-0.43	0.07	-0.07	-0.46	-0.13	-0.32	0.29	0.29
Net Receivables	0.83	0.66	0.13	-0.1	0.41	0.53	0.55	0.22	0.33	-0.28		0.46	0.53	0.41	0.26	0.11	0.24	0.44	0.21	0.37	0.25	0.25
Net Tangible Assets	0.31	0.33	-0.42	0.52	0.42	0.19	0.47	0.06	0.59	-0.46	0.46		0.67	0.81	0.44	0.31	-0.29	0.63	-0.18	0.89	0.62	0.62
Good Will	0.21	0.02	0.2	0.6	0.48	0.45	0.24	0.07	0.2	0.22	0.53	0.67		0.63	-0.06	0.6	-0.45	0.16	-0.42	0.55	0.82	0.82
Net Invested Capital	0.38	0.18	-0.39	0.41	0.44	0.49	0.62	0.08	0.66	-0.25	0.41	0.81	0.63		0.59	0.38	-0.22	0.36	-0.29	0.9	0.58	0.58
Net Working Capital	0.58	0.42	-0.75	-0.37	0.54	0.39	0.86	-0.05	0.88	-0.43	0.26	0.44	-0.06	0.59		-0.49	0.53	0.73	0.49	0.73	-0.01	-0.01
Intangible Assets	-0.25	-0.26	0.39	0.81	-0.33	0.03	-0.35	0.15	-0.32	0.07	0.11	0.31	0.6	0.38	-0.49		-0.85	-0.52	-0.91	0.06	0.45	0.45
Property Plant Equipment	0.55	0.4	-0.26	-0.93	0.39	0.32	0.54	-0.2	0.4	-0.07	0.24	-0.29	-0.45	-0.22	0.53	-0.85		0.45	0.95	-0.03	-0.39	-0.39
Long Term Debt	0.54	0.55	-0.58	-0.22	0.64	0.18	0.69	-0.09	0.72	-0.46	0.44	0.63	0.16	0.36	0.73	-0.52	0.45		0.59	0.68	0.15	0.15
Short Long Term Debt	0.45	0.42	-0.3	-0.84	0.43	0.16	0.47	-0.19	0.38	-0.13	0.21	-0.18	-0.42	-0.29	0.49	-0.91	0.95	0.59		0.01	-0.3	-0.3
Capital Stock	0.42	0.3	-0.61	0.27	0.63	0.39	0.72	0.05	0.84	-0.32	0.37	0.89	0.55	0.9	0.73	0.06	-0.03	0.68	0.01		0.58	0.58
Capital Surpluse	-0.06	-0.11	0.07	0.63	0.51	0.29	0.18	0.11	0.21	0.29	0.25	0.62	0.82	0.58	-0.01	0.45	-0.39	0.15	-0.3	0.58		1.0
Deferred Long Term Liab	-0.06	-0.11	0.07	0.63	0.51	0.29	0.18	0.11	0.21	0.29	0.25	0.62	0.82	0.58	-0.01	0.45	-0.39	0.15	-0.3	0.58	1.0

Click cells to compare fundamentals

About Avalo Therapeutics Financial Statements

Avalo Therapeutics investors use historical fundamental indicators, such as Avalo Therapeutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Avalo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	26.30	24.98
Tangible Book Value Per Share	(11.51)	(10.94)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC